Urological Cancer Clinical Trials
InPACT: International penile advanced cancer trial - an International Rare Cancers Initiative study.
TIGER: A randomised phase III trial comparing conventional dose chemotherapy using paclitaxel, ifosfamide and cisplatin (TIP) with high dose chemotherapy using mobilising paclitaxel plus ifosfamide followed by high dose carboplatin and etoposide (TI-CE) as first treatment in relapsed or refractory germ cell tumours.
Open to recruitment
CALIBER: Phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer.
PACE: International randomised study of laparoscopic prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for early stage organ-confined prostate cancer.
POUT: Peri-Operative chemotherapy or sUrveillance in upper Tract urothelial cancer.
PROMPTS: Prospective randomised phase III study of observation versus screening MRI and pre-emptive treatment in castrate resistant prostate cancer patients with spinal metastasis.
RAIDER: Randomised phase II trial of adaptive image guided standard or dose escalated tumour boost radiotherapy in the treatment of transitional cell carcinoma of the bladder.
RE-AKT: Randomised phase II study of enzalutamide (MDV3100) in combination with AZD5363 in patients with metastatic castration resistant prostate cancer.
REASURE: Phase II open label study of biomarkers to assess response in patients with metastatic castration-resistant prostate cancer treated with radium-223.
TOPARP: Phase II trial of olaparib in patients with advanced castration resistant prostate cancer.
VinCaP: Phase II trial of vinflunine chemotherapy in locally advanced and metastatic carcinoma of the penis.
In active follow-up
111 Trial: The 111 trial is a single group trial evaluating one cycle of adjuvant BEP chemotherapy in high risk, stage 1 non-seminomatous germ cell tumours of the testis (NSGCTT).
A-PREDICT: Phase II study of axitinib in patients with metastatic renal cell cancer unsuitable for nephrectomy.
BC2001: Randomised phase II study of radiotherapy with and without synchronous chemotherapy in muscle invasive bladder cancer.
BOXIT: This trial is a randomised phase III multi-centre double-blind placebo-controlled clinical trial. The primary objective is to determine if the addition of the oral COX-2 inhibitor celecoxib to standard therapy is more effective in terms of disease recurrence at 3 years compared to standard therapy alone for the treatment of superficial TCC of the bladder in intermediate and high risk patients.
CHHiP: Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer.
HYBRID: A multicentre, randomised phase II study of hypofractionated bladder radiotherapy with or without image guided adaptive planning.
LopeRA: LopeRA is a randomised controlled trial of laparoscopic, open and robot assisted prostatectomy as treatment for organ-confined prostate cancer.
Penile TPF: A Phase II Trial of docetaxel, cisplatin & 5-fluorouracil chemotherapy (TPF) in locally advanced and metastatic carcinoma of the penis.
PIVOTAL: PIVOTAL - A randomised phase II trial of Prostate and pelvIs versus prOstaTe Alone treatment for Locally advanced prostate cancer.
SPARE: Randomised trial of Selective bladder Preservation Against Radical Excision (cystectomy) in muscle invasive T2/T3 transitional cell carcinoma of the bladder – feasibility study.
Intercontinental: Intercontinental is an international phase III randomised trial comparing intermittent versus continuous androgen suppression for patients with prostate-specific-antigen progression in the clinical absence of distant metastases following radiotherapy for prostate cancer.
ProSTART: A Pilot Study for a Phase III Clinical Trial in Patients with Favourable Risk Prostate Cancer Comparing Active Surveillance Therapy Against Radical Treatment.